Clostridium difficile infection when associated with inflam-matory bowel disease (IBD) carries a higher mortality than in the absence of underlying IBD (1).  While the use of anti-biotics is a well-known risk factor for this infection, so too are the use of proton pump inhibitors, in the peri-partum and postoperative periods (4).  The incidence of C difficile infec-tion has more than doubled in the United States of America (USA) since 1996 (5).  Unresponsiveness to treatment as well as disease recurrence occur with equal frequency following conventional treatment with metronidazole and oral vanco-mycin.  Twenty to thirty per cent of patients relapse after being treated with either of these agents (6).  A recent sys-tematic review of the use of fecal bacteriotherapy in patients with recurrent disease revealed that this form of treatment is associated with a 92% cure rate.